Spinal drug delivery

Current Pain and Headache Reports

Volumn 5, Issue 6, 2001, Pages 510-516

  Grabow, Theodore S ^a   Derdzinski, David ^a   Staats, Peter S ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Baclofen; Bupivacaine; Cancer Pain; Morphine; Neuropathic Pain

Indexed keywords

ANALGESIC AGENT;

CHRONIC DISEASE; DRUG COMBINATION; HUMAN; INTRASPINAL DRUG ADMINISTRATION; PAIN; REVIEW;

ANALGESICS; CHRONIC DISEASE; DRUG THERAPY, COMBINATION; HUMANS; INJECTIONS, SPINAL; PAIN;

EID: 0035656145     PISSN: 15313433     EISSN: 15343081     Source Type: Journal    
DOI: 10.1007/s11916-001-0068-0     Document Type: Article

References (52)

1. National Pain Survey. Louis Harris and Associates Inc., for Ortho-McNeil Pharmaceuticals; 1999.
2. Roadblocks to Relief. American Pain Society—What’s New [Online] April. Available at: http://www.ampainsoc.org/ whatsnew/toc_road.htm. Accessed 2001.
3. Webster BS, Snook SH: The cost of compensable low back pain. J Occup Med 1990, 32:13–15. DOI: 10.1097/00043764-199001000-00007
4. Onofrio BM, Yaksh TL, Arnold PG: Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin Proc 1981, 56:516–520.
5. Hassenbusch SJ, Stanton-Hicks M, Covington EC, et al.: Longterm intraspinal infusions of opioids in the treatment of neuropathic pain. J Pain Symptom Manage 1995, 10:527–543. DOI: 10.1016/0885-3924(95)00087-F
6. Anderson VC, Burchiel KJ: A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery 1999, 44:289–300. DOI: 10.1097/00006123-199902000-00026
7. Goodman RR, Brisman R: Treatment of lower extremity reflex sympathetic dystrophy with continuous intrathecal morphine infusion. Appl Neurophysiol 1987, 50:425–426. DOI: 10.1159/000100752
8. Coombs DW, Saunders RL, Fratkin JD, et al.: Continuous intrathecal hydromorphone and clonidine for intractable cancer pain. J Neurosurg 1986, 64:890–894.
9. Harvey SC, O’Neil MG, Pope CA, et al.: Continuous intrathecal meperidine via an implantable infusion pump for chronic, nonmalignant pain. Ann Pharmacother 1997, 31:1306–1308.
10. Max MB, Inturrisi CE, Kaiko RF, et al.: Epidural and intrathecal opiates: cerebrospinal fluid and plasma profiles in patients with chronic cancer pain. Clin Pharmacol Ther 1985, 38:631–641. DOI: 10.1038/clpt.1985.237
11. Meignier M, Ganansia MF, Lejus C, Testa S: Intrathecal morphine therapy in children with cancer. Cah Anesthesiol 1992, 40:487–490.
12. Devulder J: Hyperalgesia induced by high-dose intrathecal sufentanil in neuropathic pain. J Neurosurg Anesthesiol 1997, 9:146–148.
13. Oyama T, Jin T, Yamaya R, et al.: Profound analgesic effects of beta-endorphin in man. Lancet 1980, 1:122–124. DOI: 10.1016/S0140-6736(80)90606-6
14. Moulin DE, Max MB, Kaiko RF, et al.: The analgesic efficacy of intrathecal D-Ala2-D-Leu5-enkephalin in cancer patients with chronic pain. Pain 1985, 23:213–221. DOI: 10.1016/0304-3959(85)90099-5
15. Wen HL, Mehal ZD, Ong BH, Ho WK: Treatment of pain in cancer patients by intrathecal administration of dynorphin. Peptides 1987, 8:191–193. DOI: 10.1016/0196-9781(87)90186-0
16. Schoeffler P, Auroy P, Bazin JE, et al.: Subarachnoid midazolam: histologic study in rats and report of its effect on chronic pain in humans. Reg Anesth 1991, 16:329–332.
17. Borg PA, Krijnen HJ: Long-term intrathecal administration of midazolam and clonidine. Clin J Pain 1996, 12:63–68. DOI: 10.1097/00002508-199603000-00012
18. Zuniga RE, Schlicht CR, Abram SE: Intrathecal baclofen is analgesic in patients with chronic pain. Anesthesiology 2000, 92:876–880. The GABA-B agonist, baclofen, produces powerful antinociception in diverse animal models of acute and chronic pain. Although intrathecal baclofen is an effective treatment for spasticity in humans, it is a poor analgesic when used for the management of chronic pain. This study demonstrates that intrathecal baclofen produces analgesia in patients with neuropathic pain and suggests a renewed place for this class of analgesic in the clinical setting. DOI: 10.1097/00000542-200003000-00037
19. Tumber PS, Fitzgibbon DR: The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidine. Pain 1998, 78:217–220. DOI: 10.1016/S0304-3959(98)00133-X
20. Mironer YE, Tollison CD: Methadone in the intrathecal treatment of chronic nonmalignant pain resistant to other neuroaxial agents: the first experience. Neuromodulation 2001, 4:25–31. DOI: 10.1046/j.1525-1403.2001.00025.x
21. Siddall PJ, Gray M, Rutkowski S, Cousins MJ: Intrathecal morphine and clonidine in the management of spinal cord injury pain: a case report. Pain 1994, 59:147–148. DOI: 10.1016/0304-3959(94)90059-0
22. Eisenach JC, Hood DD, Curry R: Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicininduced pain and hyperalgesia iin normal volunteers. Anesth Analg 1998, 87:591–596. DOI: 10.1097/00000539-199809000-00018
23. Sjoberg M, Appelgren L, Einarsson S, et al.: Long-term intrathecal morphine and bupivacaine in “refractory” cancer pain. I. Results from the first series of 52 patients. Acta Anaesthesiol Scand 1991, 35:30–43.
24. Nitescu P, Dahm P, Appelgren L, Curelaru I: Continuous infusion of opioid and bupivacaine by externalized intrathecal catheters in long-term treatment of “refractory” nonmalignant pain. Clin J Pain 1998, 14:17–28. DOI: 10.1097/00002508-199803000-00004
25. Penn RD, Paice JA: Adverse effects associated with the intrathecal administration of ziconotide. Pain 2000, 85:291–296. DOI: 10.1016/S0304-3959(99)00254-7
26. Brose WG, Gutlove DP, Luther RR, et al.: Use of intrathecal SNX-111, a novel, N-type, voltage-sensitive, calcium channel blocker, in the management of intractable brachial plexus avulsion pain. Clin J Pain 1997, 13:256–259. Omega-conotoxins are N-type voltage-sensitive calcium channel antagonists that produce antinociception in animals and analgesia in humans after spinal injection. In this study, ziconotide (SNX-111) was administered by spinal infusion to a patient with brachial plexus avulsion. Severe side effects such as nystagmus and dizziness were dose-dependent and diminished by gradual dose reduction. This study describes the clinical use of this novel class of anti-hyperalgesic and anti-allodynic agents for the treatment of chronic neuropathic pain in humans. DOI: 10.1097/00002508-199709000-00012
27. Staats PS, Luthardt F, Shipley J, et al.: Long-term intrathecal ziconotide therapy: a case study and discussion. Neuromodulation 2001, 4:121–126. DOI: 10.1046/j.1525-1403.2001.00121.x
28. Yang CY, Wong CS, Chang JY, Ho ST: Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 1996, 43:379–383.
29. Kristensen JD, Svensson B, Gordh T Jr: The NMDA-receptor antagonist CPP abolishes neurogenic “wind-up pain” after intrathecal administration in humans. Pain 1992, 51:249–253. DOI: 10.1016/0304-3959(92)90266-E
30. Penn RD, Paice JA, Kroin JS: Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain 1992, 49:13–19. DOI: 10.1016/0304-3959(92)90182-B
31. Paice JA, Penn RD, Kroin JS: Intrathecal octreotide for relief of intractable nonmalignant pain: 5 -year experience with two cases. Neurosurgery 1996, 38:203–207. DOI: 10.1097/00006123-199601000-00047
32. Karlesten R, Gordh T Jr: An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection. Anesth Analg 1995, 80:844–847. DOI: 10.1097/00000539-199504000-00037
33. Klamt JG, Garcia LV, Prado WA: Analgesic and adverse effects of a low dose of intrathecally administered hyperbaric neostigmine alone or combined with morphine in patients submitted to spinal anaesthesia: pilot studies. Anaesthesia 1999, 54:27–31. DOI: 10.1046/j.1365-2044.1999.00634.x
34. Devoghel JC: Small intrathecal doses of lysine-acetylsalicylate relieve intractable pain in man. J Int Med Res 1983, 11:90–91.
35. Pellerin M, Hardy F, Abergel A, et al.: Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases. Presse Med 1987, 16:1465–1468.
36. Yaksh TL, Onofrio BM: Retrospective consideration of the doses of morphine given intrathecally by chronic infusion in 163 patients by 19 physicians. Pain 1987, 31:211–223. DOI: 10.1016/0304-3959(87)90037-6
37. Paice JA, Penn RD, Shott S: Intraspinal morphine for chronic pain: a retrospective multicenter study. J Pain Symptom Manage 1996, 11:71–80. DOI: 10.1016/0885-3924(95)00099-2
38. Hassenbusch SJ, Portenoy RK: Current practices in intraspinal therapy—a survey of clinical trends and decision making. J Pain Symptom Manage 2000, 20:S4-S11. The investigators used an Internet-based survey to characterize the practice patterns of pain practitioners who use intrathecal therapy for the management of chronic pain. The survey demonstrated that practice patterns vary widely among practitioners who use spinal infusion therapy. This report highlights the need for improved research outcomes that can be used as a guideline for the use of this mode of therapy. DOI: 10.1016/S0885-3924(00)00203-7
39. Rawal N, Nuutinen L, Raj PP, et al.: Behavioral and histopathologic effects following intrathecal administration of butorphanol, sufentanil, and nalbuphine in sheep. Anesthesiology 1992, 77:605–607. DOI: 10.1097/00000542-199209000-00039
40. Herman RM, D’Luzansky SC, Ippolito R: Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. Clin J Pain 1992, 8:338–345. DOI: 10.1097/00002508-199212000-00008
41. Coffey JR, Cahill D, Steers W, et al.: Intrathecal baclofen for intractable spasticity of spinal origin: results of a long-term multicenter study. J Neurosurg 1993, 78:226–232. DOI: 10.3171/jns.1993.78.2.0226
42. Middleton JW, Siddall PJ, Walker S, et al.: Intrathecal clonidine and baclofen in the management of spasticity and neuropathic pain following spinal cord injury: a case study. Arch Phys Med Rehabil 1996, 77:824–826. DOI: 10.1016/S0003-9993(96)90264-6
43. Sjoberg M, Karlsson PA, Nordborg C, et al.: Neuropathologic findings after long-term intrathecal infusion of morphine and bupivacaine for pain treatment in cancer patients. Anesthesiology 1992, 76:173–186. DOI: 10.1097/00000542-199202000-00004
44. Meynadier J, Chrubasik J, Dubar M, Wunsch E: Intrathecal somatostatin in terminally ill patients. A report of two cases. Pain 1985, 23:9–12. DOI: 10.1016/0304-3959(85)90224-6
45. Klamt JG, Dos Reis MP, Barbieri NJ, Prado WA: Analgesic effect of subarachnoid neostigmine in two patients with cancer pain. Pain 1996, 66:389–391. DOI: 10.1016/0304-3959(96)03045-X
46. Bannon AW, Decker MW, Holladay MW, et al.: Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science 1998, 279:77–81. ABT-594 is a neuronal nicotinic acetylcholine receptor ligand that produces powerful antinociception in animal models of acute thermal, persistent chemical, and neuropathic pain states. Unlike morphine, repeated treatment with ABT-594 was not associated with withdrawal or physical dependence. These favorable properties suggest a potential role for this class of analgesic in chronic infusion paradigms in humans. DOI: 10.1126/science.279.5347.77
47. Burnstock G: P2X receptors in sensory neurones. Br J Anaesth 2000, 84:476–488. P2X3 receptors are expressed selectively on small-diameter sensory-specific afferent neurons. P2X3 receptors are downregulated after neuropathic injury in animals and may be regulated by certain neurotrophic factors. As such, this subclass of purinergic receptors represents a novel substrate for the development of putative analgesics.
48. Waxman SG: The molecular pathophysiology of pain: abnormal expression of sodium channel genes and its contributions to hyperexcitability of primary sensory neurons. Pain 1999, 6:S133-S140. DOI: 10.1016/S0304-3959(99)00147-5
49. Lazorthes Y, Sagen J, Sallerin B, et al.: Human chromaffin cell graft into the CSF for cancer pain management: a prospective phase II clinical study. Pain 2000, 87:19–32. DOI: 10.1016/S0304-3959(00)00263-3
50. Dougherty PM, Staats PS: Intrathecal drug therapy for chronic pain: from basic science to clinical practice. Anesthesiology 1999, 91:1891–1918. DOI: 10.1097/00000542-199912000-00044
51. Mantyh PW, Rogers SD, Honore P, et al.: Inhibition of hyperalgesia by ablation of lamina I spinal neurons expressing the substance P receptor. Science 1997, 278:275–279. Rexed lamina I of the spinal cord dorsal horn is a primary site for the integration and relaying of sensory information. Neurons in these superficial laminae express the substance P receptor, which transmits noxious input to higher brain structures. In this study, a substance P receptor, cytotoxin, was injected into the subarachnoid space, and this toxin markedly attenuated behavioral responses to noxious stimuli. These results demonstrate the potential role of neuronal cellular toxins as selective targets for the treatment of intractable pain. DOI: 10.1126/science.278.5336.275
52. Bennett G, Serafini M, Burchiel K, et al.: Evidence-based review of the literature on intrathecal delivery of pain medication. J Pain Symptom Manage 2000, 20:S12-S36. DOI: 10.1016/S0885-3924(00)00204-9